A large prospective study assessing the clinical factors associated with poor humoral response following primary SARS-COV-2 vaccination in patients with rheumatic and musculoskeletal diseases on immunosuppression
Latest Information Update: 30 Jun 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 30 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism